Vitae's accomplished team has significant experience discovering, developing and commercializing highly successful drugs in multiple therapeutic areas. Vitae's business and R&D teams are supported by a sophisticated group of investors and advisors.

Jeffrey S. Hatfield
Chief Executive Officer

Richard Gregg, M.D.
Chief Scientific Officer

Tina Fiumenero
Chief Financial Officer

Christine Brennan, Ph.D.
Chief Business Officer

David A. Claremon, Ph.D..
Vice President
Chemistry

Gerard M. McGeehan, Ph.D.
Vice President
Biology

Jeffrey S. Hatfield, Chief Executive Officer. Prior to joining VITAE PHARMACEUTICALS, Inc., Mr. Hatfield spent 19 years at Bristol-Myers Squibb, Inc. in a variety of operating positions of increasing responsibility. Most recently, he was Senior Vice President of one of the most successful BMS divisions, the $1 billion Virology/Immunology Division, where Mr. Hatfield was responsible for sales, marketing, policy and medical strategy within the HIV, hepatitis and RA therapeutic categories. Previously, he held positions including President and General Manager, BMS-Canada, and Vice President, Managed Health Care. Mr. Hatfield holds a BS in Pharmacy from Purdue University and an MBA from the Wharton School, University of Pennsylvania.

Richard Gregg, M.D., Chief Scientific Officer. Prior to joining VITAE PHARMACEUTICALS, Inc., Dr. Gregg spent 19 years leading various groups at Bristol-Myers Squibb Research and Development. For the last seven years, he was Vice President of Clinical Discovery where he was responsible for Early Clinical Development, Clinical Pharmacology, Translational Medicine, and Biomarker Technologies. During that time, Dr. Gregg developed and led the BMS efforts in the application of cutting edge science and analytical technologies to the clinical investigation of new drugs. Prior to that, he was Vice President of Metabolic and Cardiovascular Drug Discovery where the focus was on discovery of new drugs for diabetes, dyslipidemia, and atherosclerotic vascular disease. Before coming to BMS, Dr. Gregg spent ten years at the National Heart, Lung, and Blood Institute in Bethesda, MD where he studied disorders of lipid and lipoprotein metabolism. Dr. Gregg has more than 120 publications in leading medical and research journals, and has presented his research findings at national an d international meetings throughout the world. Dr. Gregg earned his BS and MS from Iowa State University and his MD from Stanford University School of Medicine. He did his internship and residency in Internal Medicine at Strong Memorial Hospital in Rochester, NY, and completed his fellowship in Endocrinology and Metabolism at the National Institutes of Health. Dr. Gregg is board certified in Internal Medicine and in Endocrinology and Metabolism.

Tina Fiumenero, Chief Financial Officer. Prior to joining VITAE PHARMACEUTICALS, Ms. Fiumenero spent 13 years at Bristol-Myers Squibb where most recently she served as Sr. Director Finance, US Primary Care leading a finance organization supporting over $5 billion in sales. Ms. Fiumenero held a number of finance positions of increasing responsibility at Bristol-Myers Squibb spanning commercial operations, mergers and acquisitions and manufacturing. Prior to joining Bristol-Myers Squibb, Ms. Fiumenero worked as a financial auditor for Coopers & Lybrand. She holds a B.S. degree in accounting from New York University and is a Certified Public Accountant.

Christine Brennan, Ph.D., Chief Business Officer. Prior to joining Vitae Pharmaceuticals, Dr. Brennan spent 4.5 years at Novartis Institutes for BioMedical Research, Inc. in the Strategic Alliances group in positions of increasing responsibility, including, most recently, as Executive Director and Head of Strategy & Operations. Prior to joining Novartis, Dr. Brennan served as Director of Business Development at the biopharmaceutical company, EnVivo Pharmaceuticals, Inc. Prior to EnVivo, she was Director at Fidelity Biosciences Group, a venture capital company. Prior to Fidelity she was a Strategic Planning Analyst and then promoted to Product Manager for Cardizem LA (hypertension drug) at Biovail Corporation. Prior to Biovail, Dr. Brennan was Scientific Analyst in the business development group at Cogent Neuroscience, Inc., a start-up biotechnology company. She received her Ph.D. in neuroscience from Dartmouth Medical School in 1995 and completed a postdoctoral fellowship at the National Institutes of Health in 1999.

David A. Claremon, Ph.D., Vice President of Chemistry. Dr. Claremon has over 20 years of experience in Medicinal Chemistry at Merck & Co. where he was Senior Director, Medicinal Chemistry, prior to joining VITAE PHARMACEUTICALS, Inc. While at Merck, his research group successfully identified several development candidates including an anti-arrhythmic (MK-499) and an oral fibrinogen receptor antagonist (L-738,167). He has authored over 50 publications and is an inventor on 65 patents. He has a Bachelors degree in chemistry from Case Western Reserve University and a Ph.D. from the University of Pennsylvania in Organic Chemistry under the direction of Professor K.C. Nicolaou.

Gerard M. McGeehan, Ph.D., Vice President of Discovery Biology. Prior to joining VITAE PHARMACEUTICALS, Inc., Dr. McGeehan was Executive Director of Lead Discovery at the DuPont Pharmaceuticals Company in Wilmington, Delaware. In 1988, he joined Glaxo Inc. (RTP), where he last served as head of the Biochemistry Department. He moved to Rhone-Poulenc Rorer in 1995, where he served as Director of Inflammation and established the Department of Lead Generation. Dr. McGeehan's research interests have included the pharmacology of proteolytic enzymes and receptors, new assay methods and exploration of problems at the biology/chemistry interface. Dr. McGeehan received his Ph.D. in organic chemistry from Stanford University and served as an NSF post-doctoral fellow at the ETH-Zurich.

[back to top]